Abstract. Radioimmunotherapy (RIT) uses an antibody labeled with a radionuclide to deliver cytotoxic radiation to a target tumor cells. Radioiodine is most commonly employed to prepare radiolabeled proteins (antibodies, peptides) for in vitro and in vivo applications. A major shortcoming of radioiodinated proteins prepared by direct labeling methods is their deiodination in vivo. For the preparation of more stable radioiodinated antibodies, we developed a new linker (N-(4-isothiocyanatobenzyl)-2-(3-(tributylstannyl)phenyl) acetamide (IBPA 
Introduction
About half of all newly diagnosed cancer cases are not healed by means of conventional treatment, such as surgery, chemotherapy, and radiotherapy. The major cause is the existence of residual tumor cells and metastases, which can give rise to a relapse of the primary tumor or new tumors somewhere else in the body. Metastases might consist of only a few malignant cells, and can thus avoid detection and removal. In some cases, systemic treatment with chemotherapeutics can be of some aid but the lack of specificity, in combination with an unacceptable level of general toxicity, often prevents this from being a curative treatment. It would appear that the solution should involve selective delivery of cytotoxic substances to tumor cells, thus saving the healthy tissues from damage. Access based on this reasoning is called 'tumor targeting' (1, 2) .
Radioimmunotherapy, a therapeutic modality in which radiolabeled monoclonal antibodies (mAbs) are used to selectively target ionizing radiation to tumor cells, has principally involved the β emitter. The radiolabel has advantages and disadvantages warranting use, possibly for different applications (3, 4) .
Iodine-131 has been the primary radionuclide for radioimmunotherapy, in part because labeling methods are rapid, simple and high specific radioactivity of products is achievable (3) . An advantage of using iodine nuclides for labeling mAbs is the availability of multiple nuclides ( 123 I, 124 I, 125 I, 131 I) with useful decay characteristics (5) . The direct radioiodination of Abs is well established and the most common procedure is the in situ generation of radioiodine from radioiodide by suitable oxidants such as chloramine-T and iodogen methods (6) .
Early experiments with tumor-targeting and targeted radionuclide therapy were performed using I-131 as label (7) . The low price and availability of I-131 are compelling features also playing an important role, and it is currently the most widely used therapeutic nuclide (8) . In addition, the highest reported response rates, complete response rates, and longest response durations reported with radioimmunoconjugates have been observed in clinical trials using I-131 as the therapeutic nuclide (9) (10) (11) .
The most significant disadvantage of radioiodinated Abs is their rapid deiodination in vivo by the action of specific enzymes, probably because of the structural similarity between these iodophenyl groups and thyroid hormones (12) . The decomposition of label from radioiodinated Abs is reflected by the uptake of free iodide in thyroidal glands and stomach. The catabolic product of radioiodinated Ab, monoiodotyrosine, is able to diffuse out of target cells. This leads to shortened residence times and correspondingly lower radiation doses delivered to the tumor target (13, 14) .
To resolve this problem, previous research developed a method that decreases the structural similarity of the labeling site on the Ab to these enzymatically degradable substrates by avoiding substitution of the iodine ortho to a hydroxyl group on an aromatic ring (tyrosine residue of the antibody) (12) . After radioiodination and conjugation to Abs, these labeling linkers provide products with greater stability when used in vivo than the directly radioiodinated products (14) .
We have designed and synthesized a new bi-functional linker for radiohalogenation of antibodies, N-(4-isothiocyanatobenzyl)-2-(3-(tributylstannyl)phenyl)acetamide (IBPA, patent no. 10-1550399KR). Isothiocyanate was introduced for structural stability both in water and most solvents. herein we present a comparative study on evaluating usefulness of IBPA as a linker for the stable radioiodinated internalizing mAb, cetuximab.
Materials and methods
Radioiodination of IBPA. Na 125 I in 0.1 N NaOh (Perkin-Elmer, Inc., Waltham, MA, uSA) was added to 100 µl of IBPA (1 mg/ml in dimethylsulfoxide, DMSO) and followed by 10 µl of chloramine T (1 mg/ml in water). After 10-15 min at room temperature, the reaction was quenched with 10 µl of sodium metabisulfite (2.5 mg/ml in water). The radioiodinated compound ([ 125 I]-IBPA) was purified by high performance liquid chromatography (HPLC). The reaction mixture was loaded on a uBondaPak™ C 18 column (300x3.9 mm, 10 µm) and eluted using the linear gradient of 65-90% acetonitrile over 30 min with flow rate of 1.0 ml/min. 
Radioiodination of cetuximab. [
125 I]-cetuximab was prepared by direct labeling of cetuximab with iodine-125. Cetuximab (12 µl; 5 mg/ml) in Buph phosphate buffer (ph 7.2) was added to Na 125 I in 0.1 N NaOh, followed by 10 µl of chloramine-T (1 mg/ml, in Buph phosphate buffer). After standing for 20 sec at room temperature, the reaction was terminated with 10 µl of sodium metabisulfite (2.5 mg/ml). The labeled mAbs were isolated by a Zeba™ Spin desalting column, 75 µl (Thermo Fisher Scientific, Waltham, MA, USA) using BupH phosphate buffer as running buffer. Radiochemical purity was measured by radio-TLC. shaking water bath (TAITEC, Saitama-ken, Japan) at 37˚C with 40 rpm agitation. One milliliter of acetonitrile was added to the mixture and incubated for 0.5, 1, 2, 4 and 8 h (n=3 each) after the incubation. Samples acquired prior to acetonitrile addition and at the various times were mixed on a vortex mixer for 1 min and centrifuged for 10 min at 13,200 rpm, 4˚C in a model 5810R apparatus (Eppendorf, hamburg, Germany). The supernatants and precipitants were separately collected. Their radioactivities were measured by a gamma counter (Perkin-Elmer, Inc.). After pre-incubation of the mixture for 3 min in a shaking water bath at 37˚C with 40 rpm agitation, the reaction was initiated by adding 10 µl of 10 mM NADPh. Adding 1 ml of acetonitrile to the mixture, the reaction was terminated prior to and 5, 10, and 30 min (n=3 each) after the incubation. The samples were mixed on a vortex mixer for 1 min and centrifuged for 10 min at 13,200 rpm, 4˚C. The supernatants were transferred to a glass tube. Their radioactivity was counted with a gamma counter (Perkin-Elmer, Inc.).
Stability of [
Cell lines and cultures. LS174T human colon cancer, PC9 human lung cancer, and FaDu squamous cell carcinoma cell lines, which all overexpress epidermal growth factor receptor, were purchased from the American Type Culture Collection (ATCC, Manassas, vA, uSA). All cells were grown in Hyclone™ DMEM (Thermo Fisher Scientific) supplemented with 10% fetal bovine serum (FBS; JR Scientific, Woodland, CA, USA) and 1% antibiotics (Thermo Fisher Scientific). The medium was changed twice or three times per week. The cells were cultured at 37˚C in a 5% CO 2 atmosphere. PBS) . The radioactivity bound to the cells was counted with a Wizard gamma counter (Perkin-Elmer, Inc.). The immunoreactivity of radiolabeled Ab was estimated as described previously (15) .
Cell binding assay.
Internalization assay. For internalization assays, LS174T cells were harvested and seeded on 6-well plates (100,000-300,000 cells/well, 1 ml). After overnight incubation, 1 µg of radiolabeled Ab (0.07 MBq) in 10 µl was added to each well and incubated for 1, 4, and 24 h at 37˚C (n=3). Then medium was removed and the cells were gently washed with ice-cold PBS followed by the addition of ice-cold acidic stripping buffer (1 ml) and 1 M NaOh (500 µl). Radioactivity of the cell culture medium, acid washes (cell surface bound), and the cell lysates (internalized) was counted using the aforementioned gamma counter. The ratio of internal cpm/total bound cpm, % surface binding, and % internal binding to total activity were calculated using the equations below:
Internal/total bound = cpm of acid wash/cpm of (acid wash + cell lysate) [1] % surface bound = 100 x cpm of acid wash/cpm of (media + acid wash + cell lysate) [2] % internalized = 100 x cpm of cell lysate/cpm of (media + acid wash + cell lysate) [3] Tumor xenograft model. All animal experiments were approved by the pertinent committee of KIRAMS and were performed in compliance with institutional guidelines for conducting animal experiments. Five-to-six-week-old female BALB/c nu/nu mice (Central Lab. Animal, Seoul, Korea) were used for the establishment of a tumor model. LS174T cells (1x10 6 cells) suspended in 100 ml of serum-free cell culture medium were subcutaneously transplanted into the right leg of each mouse. Tumor growth was assessed by measuring the bidimensional diameters using calipers. Mice bearing subcutaneous tumors with a volume reaching ~1,000 mm 3 were used for in vivo experiments. 
. Plasma samples (10 µl) were immediately mixed with acetonitrile solution (100 µl). The samples were centrifuged at 4˚C for 10 min at 13,200 rpm. Radioactivity in the precipitant and supernatant were counted using the gamma counter. The pharmacokinetic parameters were estimated by a non-compartmental method using WinNolin ver 2.0 software (Pharsight Corp., Cary, NC, uSA).
Results

Radioiodination. [
125 I]-IBPA was prepared by the chloramine-T method and purified by preparation hPLC. The average radioiodination yield of IBPA was 79.70±3.56% (n=5). A representative hPLC chromatogram is shown in Fig. 1 Internalization assay. The results of the in vitro internalization assay are shown in Table I . At 24 h, the percentage of (Table II) . 
]-IBPA-cetuximab ---------------------------------------------------------------------------------------------------------------------------------------------------------
Discussion
Radioiodinated mAbs are a promising approach for the diagnosis and treatment of cancer (16, 17) . There is some concern about their in vivo catabolism and deiodination. Considerable interest has developed concerning the development of a new radioiodination linker that is metabolically more stable in vivo. Radioiodination linkers conjugated to Abs have been reported (18) (19) (20) (21) . These new radioimmunoconjugates have significantly lower radioiodine uptake in the thyroid in comparison with directly radioiodinated mAbs.
In this study, the superiority of the residualizing labeled mAb (N-(4-isothiocyanatobenzyl)-2-(3-(tributylstannyl) phenyl) acetamide (IBPA; patent no. 10-1550399KR) over directly radioiodinated Ab was demonstrated in vitro and in vivo. IBPA was evaluated using cetuximab in LS174T tumor xenografts that overexpressed epidermal growth factor receptor.
The yield of residualizing radioiodine labeled mAb was improved in comparison to the mAb labeled in a different manner (18) . [
125 I]-IBPA-cetuximab was very stable in human and mouse sera, with no deiodination evident (Fig. 2) . Radioactivity was still bound to the Ab. The major factor for the deiodination of proteins is the structural similarity between these iodophenyl groups and thyroid hormones, compounds that have diversely specific deiodinases. A meta-substituted aryl halide was selected to avoid the loss of iodide due to nucleophilic substitution, as discussed previously (22) .
In vitro, the immunoreactive fraction of [ 125 I]-IBPAcetuximab was about twice as high as [
125 I]-cetuximab using the chloramine-T method. Also, the internalization percentage of [
125 I]-IBPA-cetuximab was higher than [ 125 I]-cetuximab (Table I) . Tyrosine residues abound in the complementarity determining region (CDR) of antibodies (23) . Iodination of tyrosine can considerably decrease or destroy the antigenbinding capability of mAbs (24) . On the other hand, lysines are present in CDRs to a much lesser extent (25) and conjugation labeling provides better immunoreactivity of the conjugate and tumor accumulation.
The intracellular degradation of radioiodinated mAbs appears to be rapid and to lead to the excretion of radiocatabolites. In the case of directly labeled mAbs, the major ). values are presented as mean % ID/ml ± SD. % ID/ml, the percent injected dose per a milliliter of plasma.
